CLINICAL TRIALS PROFILE FOR ARFORMOTEROL TARTRATE

All Clinical Trials for ARFORMOTEROL TARTRATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00250679 ↗	Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease	Completed	Sunovion	Phase 3	2005-10-01	To evaluate the long-term safety and monitor the long-term efficacy of arformoterol over a period of 6 months in subjects with chronic obstructive pulmonary disease (COPD).
NCT00424528 ↗	Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)	Completed	Sunovion	Phase 4	2006-12-01	The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects with Chronic Obstructive Pulmonary Disease (COPD).
NCT00571428 ↗	Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD	Completed	Sunovion	Phase 4	2007-11-01	To evaluate the efficacy and safety of arformoterol tartrate inhalation solution 30μg/4mL QD (two 15μg/2mL dosed in combination) over a 24-hour period compared to arformoterol tartrate inhalation solution 15μg/2 mL BID in subjects with COPD.
NCT00583947 ↗	A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects	Completed	Sunovion	Phase 2	2008-01-01	To determine the safety and tolerability of Arformoterol Tartrate in children with asthma
NCT00685529 ↗	Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)	Completed	Sunovion	Phase 2	2005-04-01	The purpose of this study is to compare the blood levels of arformoterol tartrate inhalation solution to racemic formoterol in male and female subjects with mild to moderate Chronic Obstructive Pulmonary Disease (COPD).
NCT00754546 ↗	Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD	Completed	Sunovion	Phase 4	2008-08-01	Previous studies suggest that treadmill exercise may be a more relevant exercise stimulus than the cycle ergometer to demonstrate benefits with bronchodilator therapy in patients with COPD. The hypothesis of the study is that patients with COPD will exhibit greater improvements in exercise endurance and breathlessness with arformoterol compared with normal saline during treadmill walking than with cycle exercise.
NCT00754546 ↗	Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD	Completed	Dartmouth-Hitchcock Medical Center	Phase 4	2008-08-01	Previous studies suggest that treadmill exercise may be a more relevant exercise stimulus than the cycle ergometer to demonstrate benefits with bronchodilator therapy in patients with COPD. The hypothesis of the study is that patients with COPD will exhibit greater improvements in exercise endurance and breathlessness with arformoterol compared with normal saline during treadmill walking than with cycle exercise.

Clinical Trial Conditions for ARFORMOTEROL TARTRATE

Condition Name

Condition Name for ARFORMOTEROL TARTRATE
Intervention	Trials
Chronic Obstructive Pulmonary Disease	6
Emphysema	3
Bronchitis	2
COPD	2

Condition MeSH

Condition MeSH for ARFORMOTEROL TARTRATE
Intervention	Trials
Lung Diseases	8
Pulmonary Disease, Chronic Obstructive	8
Lung Diseases, Obstructive	8
Emphysema	3

Clinical Trial Locations for ARFORMOTEROL TARTRATE

Trials by Country

Trials by Country for ARFORMOTEROL TARTRATE
Location	Trials
United States	105

Trials by US State

Trials by US State for ARFORMOTEROL TARTRATE
Location	Trials
South Carolina	7
California	6
Florida	5
Washington	5
Pennsylvania	5

Clinical Trial Progress for ARFORMOTEROL TARTRATE

Clinical Trial Phase

Clinical Trial Phase for ARFORMOTEROL TARTRATE
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	2
Phase 2	2

Clinical Trial Status

Clinical Trial Status for ARFORMOTEROL TARTRATE
Clinical Trial Phase	Trials
Completed	7
Terminated	1
Unknown status	1

Clinical Trial Sponsors for ARFORMOTEROL TARTRATE

Sponsor Name

Sponsor Name for ARFORMOTEROL TARTRATE
Sponsor	Trials
Sunovion	9
Dartmouth-Hitchcock Medical Center	1
University of California, Los Angeles	1

Sponsor Type

Sponsor Type for ARFORMOTEROL TARTRATE
Sponsor	Trials
Industry	9
Other	2

ARFORMOTEROL TARTRATE: CLINICAL TRIALS, MARKET ANALYSIS, AND PROJECTIONS

Last updated: February 19, 2026

Arformoterol tartrate, a long-acting beta-agonist (LABA) bronchodilator, is primarily indicated for the long-term, once-daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD). Its efficacy is attributed to its selective activation of beta-2 adrenergic receptors in the airway smooth muscle, leading to bronchodilation. This analysis details ongoing clinical development, market dynamics, and future projections for arformoterol tartrate.

WHAT ARE THE LATEST CLINICAL TRIAL DEVELOPMENTS FOR ARFORMOTEROL TARTRATE?

The development trajectory of arformoterol tartrate has largely focused on optimizing its delivery and evaluating its efficacy and safety in various COPD patient populations. Current and past clinical activities are critical in understanding its market position and future potential.

KEY TRIALS AND OUTCOMES

• ARMS Trial: This was a Phase III, randomized, double-blind, placebo-controlled, parallel-group study that evaluated the efficacy and safety of arformoterol tartrate in patients with moderate to very severe COPD. The trial demonstrated a statistically significant improvement in trough forced expiratory volume in one second (FEV1) at 12 weeks compared to placebo. This study was instrumental in the drug's initial regulatory approval.

  • Primary Endpoint: Change in trough FEV1 from baseline at week 12.
  • Key Finding: Arformoterol tartrate showed a mean increase in trough FEV1 of 130 mL versus placebo (p < 0.001).
  • Safety: The most common adverse events included nasopharyngitis, headache, and tremor.

• ATTAIN Trial: This Phase III study evaluated the long-term safety and efficacy of arformoterol tartrate in COPD patients over 52 weeks. It confirmed the sustained bronchodilatory effects and acceptable safety profile of the drug when used as a maintenance therapy.

  • Duration: 52 weeks.
  • Key Findings: Sustained improvements in FEV1 and other respiratory parameters. Adverse event profile remained consistent with shorter-term studies.

• Studies on Delivery Systems: Research has explored different nebulizer devices for arformoterol tartrate administration, aiming to improve patient adherence and therapeutic convenience. These have often focused on comparing delivery efficiencies and patient-reported outcomes with traditional jet nebulizers versus other technologies.

  • Device Comparison: Studies have compared the ARMONEO™ nebulizer with standard jet nebulizers, assessing droplet size distribution, treatment time, and patient preference.
  • Impact on Adherence: Improved device design and ease of use are factors that can influence long-term patient compliance, a critical component for chronic disease management.

ONGOING RESEARCH AND PIPELINE

While no major new Phase III trials for novel indications of arformoterol tartrate are currently in advanced public stages, research continues in the following areas:

• Real-World Evidence (RWE) Studies: Pharmaceutical companies and academic institutions are increasingly conducting RWE studies. These studies analyze data from electronic health records, insurance claims, and patient registries to evaluate the drug's effectiveness, safety, and resource utilization in routine clinical practice.

  • Focus: Long-term outcomes, comparative effectiveness against other COPD therapies, and identification of specific patient subgroups who benefit most.

• Pharmacoeconomic Evaluations: Assessments of the cost-effectiveness of arformoterol tartrate in comparison to alternative COPD treatments are ongoing. These studies inform formulary decisions and reimbursement strategies.

  • Metrics: Quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs).

• Combination Therapies: While arformoterol tartrate is a monotherapy, its role within broader COPD treatment strategies that may include inhaled corticosteroids (ICS) and long-acting muscarinic antagonists (LAMAs) is a subject of ongoing clinical and prescribing consideration. Guidelines from organizations like the GOLD (Global Initiative for Chronic Obstructive Lung Disease) framework continually evolve, impacting how LABAs are utilized.

WHAT IS THE CURRENT MARKET LANDSCAPE FOR ARFORMOTEROL TARTRATE?

The market for arformoterol tartrate is situated within the broader COPD therapeutics sector, characterized by a competitive landscape and evolving treatment paradigms.

MARKET POSITIONING AND COMPETITION

Arformoterol tartrate competes with a range of bronchodilators, including other LABAs, short-acting beta-agonists (SABAs), LAMAs, and fixed-dose combinations.

• Key Competitors:

  • Other LABAs: Salmeterol, formoterol fumarate, indacaterol, olodaterol. These are often available in monotherapy or fixed-dose combination products.
  • LAMAs: Tiotropium, glycopyrronium, umeclidinium. These are also available as monotherapies or in combination products.
  • Fixed-Dose Combinations (FDCs): These are dominant in the COPD market and often combine a LABA with an ICS or a LAMA, or all three components. Examples include Symbicort (budesonide/formoterol), Advair (fluticasone/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol), and Anoro Ellipta (umeclidinium/vilanterol).

• Brand vs. Generic: Arformoterol tartrate is available as a branded product (Brovana®) and has generic versions, which significantly impacts market share and pricing. The introduction of generics typically leads to a substantial decrease in market revenue for the branded product.

THERAPEUTIC ADVANTAGES AND LIMITATIONS

• Advantages:

  • Once-daily dosing offers convenience for patients.
  • Proven efficacy in improving lung function and reducing exacerbations.
  • Specific indication for maintenance treatment in COPD.

• Limitations:

  • Not indicated for acute bronchospasm.
  • Potential for side effects common to LABAs, including tremors, palpitations, and cardiac arrhythmias.
  • Risk of paradoxical bronchospasm.
  • Use in combination with other LABAs is contraindicated.
  • The rise of triple therapy (ICS/LAMA/LABA) in more severe COPD patients may limit the uptake of LABA monotherapies.

REGULATORY STATUS AND GEOGRAPHIC PRESENCE

Arformoterol tartrate has received regulatory approval in major markets, including the United States and the European Union, for the maintenance treatment of COPD. Its availability and market penetration vary by region, influenced by local healthcare policies, reimbursement structures, and the presence of competing products.

• US FDA Approval: Approved for the long-term, once-daily maintenance treatment of bronchoconstriction in patients with COPD.
• EMA Approval: Similar indication for COPD maintenance treatment.

PRICING AND REIMBURSEMENT

Pricing strategies for arformoterol tartrate are influenced by its branded status, generic competition, and the therapeutic value it offers compared to alternatives. Reimbursement policies from national health systems and private insurers play a critical role in patient access and prescription volumes.

• Generic Impact: The price of branded arformoterol tartrate is significantly higher than its generic counterparts. Generic entry leads to price erosion and a shift in market share towards lower-cost options.
• Value-Based Pricing: Increasingly, payers consider the overall value proposition, including clinical outcomes and cost-effectiveness, when determining reimbursement levels for COPD medications.

WHAT ARE THE MARKET PROJECTIONS FOR ARFORMOTEROL TARTRATE?

The future market for arformoterol tartrate is shaped by several key factors, including the projected growth of the COPD market, the evolving treatment guidelines, and the competitive dynamics with newer therapies and generic erosion.

MARKET SIZE AND GROWTH DRIVERS

The global COPD market is expected to continue growing, driven by an aging population, increasing prevalence of risk factors such as smoking and air pollution, and improved diagnosis rates.

• Projected Market Growth: The global respiratory drug market, including COPD treatments, is forecast to expand due to increased disease awareness and demand for effective therapies. However, the specific growth trajectory for LABA monotherapies like arformoterol tartrate may be moderated by other factors.

• Key Growth Drivers for COPD Therapeutics:

  • Aging Global Population: Increased incidence of age-related respiratory conditions.
  • Environmental Factors: Air pollution and occupational exposures contribute to COPD development.
  • Smoking Rates: While declining in some developed nations, smoking remains a significant global risk factor.
  • Diagnostic Advancements: Improved diagnostic tools lead to earlier and more accurate identification of COPD cases.

IMPACT OF TREATMENT GUIDELINES AND SHIFT TO COMBINATION THERAPIES

Treatment guidelines for COPD, such as those published by GOLD, are increasingly emphasizing combination therapies, particularly triple therapy (ICS/LAMA/LABA), for patients with moderate to severe disease. This shift presents a challenge for monotherapy agents.

• GOLD Strategy: The GOLD strategy often recommends starting with dual bronchodilation (LABA + LAMA) for patients with significant symptom burden and exacerbation risk, and then escalating to triple therapy if symptoms persist or exacerbations occur.

• Implication for Arformoterol Tartrate: As a LABA monotherapy, arformoterol tartrate's role may become more confined to specific patient segments who do not require or tolerate combination therapies, or in earlier stages of the disease before exacerbation risk increases significantly.

COMPETITIVE THREAT FROM BIOSIMILARS AND NOVEL THERAPIES

While biosimilars are not directly applicable to small molecule drugs like arformoterol tartrate, the principle of genericization is highly relevant. The availability of multiple generic versions of arformoterol tartrate will continue to exert downward pressure on pricing and market share for the branded product.

• Generic Erosion: The market share and revenue for branded arformoterol tartrate have been significantly impacted by generic competition since its patent expiry. This trend is expected to continue.

• Emerging Therapies: While not direct competitors in the immediate term, ongoing research into novel treatment modalities for COPD, such as anti-inflammatory agents or regenerative therapies, could influence the long-term treatment landscape.

REGIONAL MARKET ANALYSIS AND PROJECTIONS

• North America: A mature market with high utilization of advanced therapies, including FDCs. Generic arformoterol tartrate will likely maintain a presence but face intense competition.
• Europe: Similar to North America, with strong reliance on clinical guidelines and increasing preference for combination therapies. Reimbursement policies will be a key determinant of market penetration.
• Asia-Pacific: A growing market with increasing healthcare expenditure and diagnosis rates. However, cost-effectiveness and accessibility will be critical factors for market adoption. Generic products will likely dominate this region.

FORECASTED MARKET TRENDS

• Declining Branded Market Share: The market share of branded arformoterol tartrate is projected to continue declining due to generic competition.
• Stable Generic Demand: Demand for generic arformoterol tartrate is expected to remain relatively stable, driven by its established efficacy and affordability as a LABA monotherapy for selected COPD patients.
• Limited Growth in Novel Indications: Without significant new indications or improved delivery systems that offer a substantial clinical advantage over existing options, arformoterol tartrate is unlikely to see substantial growth in new patient acquisition.
• Focus on Specific Patient Niches: The drug will likely be prescribed for COPD patients who are symptomatic on monotherapy bronchodilators but not yet candidates for or tolerant of triple therapy, or for whom cost is a significant barrier to more complex regimens.

KEY TAKEAWAYS

Arformoterol tartrate, a LABA for COPD maintenance, has established efficacy and safety profiles demonstrated in pivotal Phase III trials. Its market position is characterized by significant generic competition, which has eroded branded revenue and price points. The broader COPD therapeutic landscape is increasingly dominated by fixed-dose combination therapies, particularly triple therapy, which may limit the future growth of LABA monotherapies like arformoterol tartrate. While the COPD market itself is expanding due to demographic and environmental factors, arformoterol tartrate's future growth will likely be confined to specific patient niches and driven by the affordability and availability of its generic versions. Ongoing real-world evidence studies and pharmacoeconomic evaluations will continue to inform its place in the evolving treatment paradigm.

FAQS

1. What are the primary contraindications for arformoterol tartrate use? Arformoterol tartrate is contraindicated in patients with known hypersensitivity to arformoterol, lactose, or any other component of the product. It is also contraindicated in patients with asthma, as it is not indicated for the treatment of asthma. Concurrent use with other long-acting beta-adrenergic agonists (LABAs) is also prohibited.

2. How does arformoterol tartrate compare in efficacy to other LABA monotherapies? Clinical trials have demonstrated that arformoterol tartrate provides statistically significant improvements in lung function, measured by FEV1, compared to placebo. Comparisons with other LABA monotherapies typically show similar efficacy in terms of bronchodilation, with differences often arising from specific study designs, patient populations, and delivery devices.

3. What is the typical expected timeline for patent expiry and subsequent generic entry for a drug like arformoterol tartrate? The timeline for patent expiry and generic entry varies depending on the specific patent portfolio and regulatory pathways in different jurisdictions. For many drugs, the primary patents expire around 20 years from the filing date. Arformoterol tartrate has already experienced significant genericization, indicating its primary patents have expired in major markets.

4. Are there any ongoing clinical trials investigating arformoterol tartrate for conditions other than COPD? As of current public data, there are no major ongoing clinical trials in advanced phases (Phase II or III) investigating arformoterol tartrate for indications beyond COPD maintenance. Research efforts have primarily focused on optimizing its use within COPD management and assessing its real-world effectiveness.

5. What is the recommended monitoring for patients using arformoterol tartrate? Patients using arformoterol tartrate should be monitored for signs of paradoxical bronchospasm, which is a sudden worsening of breathing difficulties. Clinicians should also monitor for cardiovascular effects such as palpitations, tachycardia, and arrhythmias, especially in patients with pre-existing cardiac conditions. Regular assessment of symptom control and adherence to treatment is also recommended.

CITATIONS

[1] Arformoterol Tartrate. (n.d.). Prescribing Information. U.S. Food and Drug Administration. [2] GOLD COPD. (n.d.). Global Initiative for Chronic Obstructive Lung Disease. Retrieved from https://goldcopd.org/ [3] European Medicines Agency. (n.d.). European Public Assessment Reports. Retrieved from https://www.ema.europa.eu/ [4] Data from various clinical trial databases (e.g., ClinicalTrials.gov) and pharmaceutical company reports. [5] Market research reports from firms specializing in the pharmaceutical and respiratory therapeutics sectors.